Shopping Cart (0)
My Account

 Shopping Cart
Conferences | Training Courses | Market Reports | Managed Events | Past Conferences | Update Me
SELECTBIO Conferences Circulating DNA, Circulating RNA, Circulating Tumor Cells
Conferences  \  Circulating Biomarkers World Congress 2015  \  Circulating DNA, Circulating RNA, Circulating Tumor Cells  \  Agenda  \  Phil Stephens
RegisterLogin

Phil Stephens's Biography


Phil Stephens, Chief Scientific Officer, Foundation Medicine

Dr. Stephens leads research and development at Foundation Medicine. Dr. Stephens is a world-renowned expert in next-generation sequencing and cancer genome analysis and has authored numerous publications in Nature, Nature Genetics, Nature Medicine, Cell and other high-profile journals. Since joining Foundation Medicine in early 2011 Dr Stephens has overseen the development of FoundationOne™, and FoundationOne™ Heme, comprehensive next generation sequencing diagnostic assays that accurately profiles the entire coding sequence of hundreds of cancer-related genes in the CLIA setting. Prior to joining Foundation Medicine, Dr. Stephens held various senior research positions during his 11-year tenure with the Cancer Genome Project at the Wellcome Trust Sanger Institute under the direction of Sir Professor Michael Stratton.

Phil Stephens Image

Assessing the Promise of Liquid Biopsy to Enable Detection of Druggable Genomic Alterations Using Targeted NGS Assays Optimized for CTCs and ctDNA

Monday, 23 March 2015 at 15:30

Add to Calendar ▼2015-03-23 11:00:002015-03-23 12:00:00Europe/LondonAssessing the Promise of Liquid Biopsy to Enable Detection of Druggable Genomic Alterations Using Targeted NGS Assays Optimized for CTCs and ctDNASELECTBIOenquiries@selectbiosciences.com

Circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) could enable characterization of druggable targets in blood samples from patients with cancer, especially when conventional biopsies are unobtainable, to inform selection of targeted therapies and provide insights into systemic disease.  To assess the clinical utility of the liquid biopsy, we have genomically profiled primary resections, metastatic biopsies, ctDNA and CTCs from the same patients with a diverse spectrum of solid tumors.

Add to Calendar ▼2015-03-23 00:00:002015-03-24 00:00:00Europe/LondonCirculating DNA, Circulating RNA, Circulating Tumor CellsSELECTBIOenquiries@selectbiosciences.com


Corporate Sponsors